Calithera Biosciences

OverviewSuggest Edit

Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. Calithera is currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors.

In tumor immunology, the Company's lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Calithera Biosciences's ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.

TypePublic
Founded2010
HQSouth San Francisco, CA, US
Websitecalithera.com
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2018)79(+9%)
Job Openings4
Revenue (FY, 2018)$22.3 M(-14%)
Share Price (Jun 2021)$2.3(-1%)
Cybersecurity ratingAMore

Key People/Management at Calithera Biosciences

Susan M. Molineaux

Susan M. Molineaux

Founder, President & Chief Executive Officer, Director
Keith Orford

Keith Orford

Chief Medical Officer
Christopher J. Molineaux

Christopher J. Molineaux

Senior Vice President of Development
Stephanie Wong

Stephanie Wong

Chief Financial Officer
Eric B. Sjogren

Eric B. Sjogren

Senior Vice President of Drug Discovery
Sumita Ray

Sumita Ray

General Counsel and Chief Compliance Officer
Show more

Calithera Biosciences Office Locations

Calithera Biosciences has an office in South San Francisco
South San Francisco, CA, US (HQ)
343 Oyster Point Blvd #200
Show all (1)

Calithera Biosciences Financials and Metrics

Calithera Biosciences Revenue

Calithera Biosciences's revenue was reported to be $22.25 m in FY, 2018
USD

Net income (Q1, 2021)

(20.4m)

EBIT (Q1, 2021)

(20.8m)

Market capitalization (11-Jun-2021)

168.8m

Closing stock price (11-Jun-2021)

2.3

Cash (31-Mar-2021)

101.4m

EV

70.2m
Calithera Biosciences's current market capitalization is $168.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

26.0m22.3m

General and administrative expense

5.4m9.1m10.6m12.5m13.3m16.6m20.4m

R&D expense

16.4m23.7m27.7m43.1m66.2m76.3m71.0m

Operating expense total

21.7m32.8m38.3m55.6m79.5m92.9m91.4m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

4.2m7.3m7.3m5.2m17.1m

General and administrative expense

1.3m2.2m2.3m2.2m2.6m2.7m2.3m3.3m2.8m3.1m3.5m3.5m3.1m4.2m4.0m3.9m4.9m5.1m4.7m5.4m

R&D expense

3.9m5.6m5.5m6.8m7.1m7.8m6.3m6.6m10.1m10.8m15.5m17.3m16.4m20.2m20.9m17.2m20.1m15.7m18.2m15.3m

Operating expense total

5.2m7.9m7.9m9.0m9.7m10.4m8.6m9.9m13.0m13.9m19.0m20.8m19.5m24.4m24.9m21.1m25.1m20.8m22.9m20.8m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

102.0m6.1m10.6m48.5m51.1m60.4m107.1m

Accounts Receivable

1.1m2.0m482.0k1.5m

Prepaid Expenses

2.7m2.1m2.0m2.0m

Inventories

1.9m2.6m1.8m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(21.7m)(32.6m)(38.0m)(27.8m)(54.6m)(89.9m)(90.1m)

Depreciation and Amortization

361.0k404.0k297.0k365.0k505.0k479.0k364.0k

Inventories

(1.5m)(673.0k)787.0k

Accounts Payable

543.0k(131.0k)(28.0k)674.0k175.0k816.0k(58.0k)
USDQ3, 2014

Financial Leverage

-1.1 x
Show all financial metrics

Calithera Biosciences Operating Metrics

FY, 2016

Phase I Trials Products

1

Phase I/II Trials Products

1
Show all operating metrics

Calithera Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Calithera Biosciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Calithera Biosciences Online and Social Media Presence

Embed Graph

Calithera Biosciences Company Culture

  • Overall Culture

    A+

    95/100

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Calithera Biosciences News and Updates

Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708

--CB-708 is an oral small molecule inhibitor of CD73 in preclinical development for oncology--Antengene is granted exclusive rights to develop and commercialize asset discovered and initially developed by Calithera

Calithera Biosciences to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

SOUTH SAN FRANCISCO, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that …

Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday, March 16, 2021

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that …

Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint

-- Company will continue to advance telaglenastat KEAPSAKE trial in non-small cell lung cancer, arginase inhibitor CB-280 trial in cystic fibrosis and emerging pipeline

Calithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting

IL4I1 inhibitor shows immune-mediated anti-tumor activity IL4I1 inhibitor shows immune-mediated anti-tumor activity

Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights

--Calithera to Provide Corporate Update via Conference Call and Webcast at2:00 p.m. PT on November 5, 2020-- SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel…
Show more

Calithera Biosciences Blogs

Calithera Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights

Calithera Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights Content Import Thu, 05/06/2021 - 16:11 Calithera Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights 05/06/21 This release is a backfill from a …

Results from Calithera Biosciences’ CANTATA Study to Be Presented at 2021 ASCO Annual Meeting

Results from Calithera Biosciences’ CANTATA Study to Be Presented at 2021 ASCO Annual Meeting Content Import Wed, 04/28/2021 - 07:01 Results from Calithera Biosciences’ CANTATA Study to Be Presented at 2021 ASCO Annual Meeting 04/28/21 This release is a backfi…

Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights

Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights Content Import Tue, 03/16/2021 - 16:07 Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights 03/16/21 This release is a backfill from …

UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday, March 16, 2021

SOUTH SAN FRANCISCO, Calif. , March 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that

INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium

SOUTH SAN FRANCISCO, Calif. , Jan. 11, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that

Calithera to Participate in Jefferies Virtual Healthcare Conference and SVB Leerink Oncology 1x1 Day

SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its
Show more

Calithera Biosciences Frequently Asked Questions

  • When was Calithera Biosciences founded?

    Calithera Biosciences was founded in 2010.

  • Who are Calithera Biosciences key executives?

    Calithera Biosciences's key executives are Susan M. Molineaux, Keith Orford and Christopher J. Molineaux.

  • How many employees does Calithera Biosciences have?

    Calithera Biosciences has 79 employees.

  • Who are Calithera Biosciences competitors?

    Competitors of Calithera Biosciences include SK Biopharmaceuticals, Neoleukin Therapeutics and Faron.

  • Where is Calithera Biosciences headquarters?

    Calithera Biosciences headquarters is located at 343 Oyster Point Blvd #200, South San Francisco.

  • Where are Calithera Biosciences offices?

    Calithera Biosciences has an office in South San Francisco.

  • How many offices does Calithera Biosciences have?

    Calithera Biosciences has 1 office.